Evidence map›Paper›PMID 40521518›Full record

ArticleACS omega2025

Synthesis and Pharmacological Characterization of a Novel Cannabinoid Receptor 1 Antagonist.

Iker Bengoetxea de Tena, Gorka Pereira-Castelo, Jonatan Martínez-Gardeazabal, Marta Moreno-Rodríguez, Iván Manuel, Claudio Martínez, Belén Vaz, Javier González-Ricarte, Rosana Álvarez, Angel Torres-Mozas and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Iker Bengoetxea de TenaDepartment of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa University Campus, Sarriena s/n, 48940, Leioa, Spain.ORCID https://orcid.org/0000-0003-0586-1857
Gorka Pereira-CasteloDepartment of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa University Campus, Sarriena s/n, 48940, Leioa, Spain.
Jonatan Martínez-GardeazabalDepartment of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa University Campus, Sarriena s/n, 48940, Leioa, Spain.ORCID https://orcid.org/0000-0002-0701-9076
Marta Moreno-RodríguezDepartment of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa University Campus, Sarriena s/n, 48940, Leioa, Spain.
Iván ManuelDepartment of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa University Campus, Sarriena s/n, 48940, Leioa, Spain.
Claudio MartínezCINBIO and Department of Organic Chemistry, Faculty of Chemistry, University of Vigo, Experimental Sciences Building, Lagoas-Marcosende University Campus, 36310, Vigo, Spain.
Belén VazCINBIO and Department of Organic Chemistry, Faculty of Chemistry, University of Vigo, Experimental Sciences Building, Lagoas-Marcosende University Campus, 36310, Vigo, Spain.ORCID https://orcid.org/0000-0002-7900-1430
Javier González-RicarteCINBIO and Department of Organic Chemistry, Faculty of Chemistry, University of Vigo, Experimental Sciences Building, Lagoas-Marcosende University Campus, 36310, Vigo, Spain.
Rosana ÁlvarezCINBIO and Department of Organic Chemistry, Faculty of Chemistry, University of Vigo, Experimental Sciences Building, Lagoas-Marcosende University Campus, 36310, Vigo, Spain.ORCID https://orcid.org/0000-0001-5608-7561
Angel Torres-MozasBasque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 800, 48160, Derio, Spain.
Francesca PeccatiBasque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 800, 48160, Derio, Spain.ORCID https://orcid.org/0000-0002-7813-8216
Gonzalo Jiménez-OsésBasque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 800, 48160, Derio, Spain.ORCID https://orcid.org/0000-0003-0105-4337
Angel Rodríguez de LeraCINBIO and Department of Organic Chemistry, Faculty of Chemistry, University of Vigo, Experimental Sciences Building, Lagoas-Marcosende University Campus, 36310, Vigo, Spain.
Rafael Rodríguez-PuertasDepartment of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa University Campus, Sarriena s/n, 48940, Leioa, Spain.ORCID https://orcid.org/0000-0003-4517-5114

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The endocannabinoid (eCB) system regulates several brain functions and is implicated in numerous conditions affecting the brain. Thus, the pharmacological blockade of cannabinoid receptors has a therapeutic potential but produces severe psychiatric side effects. Hence, new cannabinoid compounds with different pharmacological profiles are needed to potentially minimize this toxicity. The objective of this study, featuring original chemical insights, pharmacological analysis, and robust computational methods, was to synthesize and characterize a series of novel antagonists/inverse agonists of cannabinoid receptors. To do so, we first synthesized and then screened 11 novel compounds for affinity for cannabinoid receptors. After that, we characterized in depth the pharmacological profile of the most promising one, UVI3502, which showed affinity for two [

Identifiers

PMID40521518
PMCPMC12163822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.